Geovax Labs (Geovax Labs) Float Percentage Of Total Shares Outstanding : N/A (As of May. 26, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Geovax Labs's float shares is 0.00 Mil. Geovax Labs's total shares outstanding is 0.00 Mil. Geovax Labs's float percentage of total shares outstanding is N/A.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Geovax Labs's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Geovax Labs's Institutional Ownership is 0.00%.

Geovax Labs Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Geovax Labs's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	0.00
	=	N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geovax Labs (Geovax Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVXW) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

GOVX:USA E8L:Germany

Address

1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080

Website

https://www.geovax.com

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.